Nantahala Capital Management LLC Takes $1.03 Billion Position in Curis, Inc. $CRIS

Nantahala Capital Management LLC purchased a new stake in Curis, Inc. (NASDAQ:CRIS) during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 1,978,876 shares of the biotechnology company’s stock, valued at approximately $1,033,171,000. Nantahala Capital Management LLC owned approximately 0.95% of Curis at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently modified their holdings of the company. Stonepine Capital Management LLC bought a new position in shares of Curis during the second quarter worth about $1,729,292,000. Cable Car Capital LP bought a new stake in Curis in the 2nd quarter valued at approximately $696,000. BlackRock Inc. bought a new stake in Curis in the 2nd quarter valued at approximately $28,000. Focused Wealth Management Inc bought a new stake in Curis in the 2nd quarter valued at approximately $26,000. Finally, Flputnam Investment Management Co. acquired a new position in Curis during the 2nd quarter worth approximately $128,000. 29.97% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the stock. Wall Street Zen raised shares of Curis from a “strong sell” rating to a “hold” rating in a research note on Saturday, August 22nd. Weiss Ratings reissued a “sell (e+)” rating on shares of Curis in a research report on Friday, July 17th. HC Wainwright restated a “buy” rating on shares of Curis in a report on Monday, August 17th. Finally, Zacks Research downgraded shares of Curis from a “hold” rating to a “strong sell” rating in a research report on Tuesday, August 11th. One analyst has rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Reduce” and an average price target of $43.00.

Curis Stock Down 0.7%

Shares of Curis stock opened at $1.49 on Friday. Curis, Inc. has a 12-month low of $1.40 and a 12-month high of $39.00. The stock has a market cap of $3.11 million, a P/E ratio of -0.10 and a beta of 3.13. The business’s 50 day moving average is $4.45 and its 200-day moving average is $10.56.

Curis (NASDAQ:CRIS) last released its quarterly earnings data on Friday, August 14th. The biotechnology company reported ($4.02) EPS for the quarter, beating the consensus estimate of ($6.95) by $2.93. Curis had a negative return on equity of 2,365.94% and a negative net margin of 80.29%. On average, sell-side analysts expect that Curis, Inc. will post -24.23 EPS for the current year.

About Curis

Curis, Inc is a biotechnology company focused on the discovery, development and commercialization of targeted small molecule and antibody therapeutics for the treatment of cancer. The company’s research centers on exploiting key signaling pathways and tumor microenvironment interactions to develop compounds with the potential to address unmet medical needs. Curis’ proprietary pipeline includes multiple programs at various stages of clinical and preclinical development, reflecting its emphasis on innovative oncology drug candidates.

Among Curis’ lead assets is CA-4948, an oral inhibitor of interleukin-1 receptor–associated kinase 4 (IRAK4) partnered with Ikena Oncology, which is being evaluated in hematologic malignancies and solid tumors.